Peanut Allergy Treatment Market Size in the 7MM was Valued at ~USD 533 Million in 2025 and is Expected to Reach ~USD 2,464 Million by 2034, Growing at a CAGR of 18.50%, Estimates DelveInsight

DelveInsight's "Peanut Allergy Treatment Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Peanut Allergy, historical and forecasted epidemiology, as well as the Peanut Allergy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Peanut Allergy Treatment Market Report

- The Peanut Allergy Treatment market in the 7MM was valued at approximately USD 533 million in 2025 and is projected to grow significantly during the forecast period (2025-2034).

- The Peanut Allergy Treatment Market is expected to grow at a CAGR of 18.50%, reaching approximately USD 2,464 million by 2034 across the 7MM.

- Peanut Allergy remains one of the most common and severe food allergies, affecting nearly 1-2% of the US population and demonstrating increasing prevalence globally, especially among pediatric populations.

- In 2024, the Peanut Allergy Diagnosed Prevalent Population in the 7MM was estimated at approximately 9.8 million cases, with the United States accounting for the highest number of diagnosed prevalent cases.

- Currently, PALFORZIA and XOLAIR are the only approved Peanut Allergy therapies, providing important treatment options for both pediatric and adult populations.

- In March 2025, the US FDA approved OMLYCLO (omalizumab-igec) as the first biosimilar designated interchangeable with XOLAIR for IgE-mediated food allergy treatment.

- The Peanut Allergy pipeline is advancing rapidly with innovative therapeutic approaches including BTK inhibitors, immunostimulants, immunomodulators, immunosuppressants, and epicutaneous immunotherapies.

- Key Peanut Allergy companies such as DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Allergy Therapeutics, Intrommune Therapeutics, Roche, Regeneron Pharmaceuticals, and others are actively evaluating novel therapies.

Stay ahead in the Peanut Allergy Treatment Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Peanut Allergy Epidemiology Segmentation in the 7MM

- Total Diagnosed Prevalent Cases of Peanut Allergy

- Gender-specific Cases of Peanut Allergy

- Age-specific Cases of Peanut Allergy

- Severity-specific Cases of Peanut Allergy

- Country-wise Peanut Allergy Epidemiology

Key Factors Driving the Peanut Allergy Market

Rising Prevalence of Peanut Allergy

Peanut Allergy is among the most prevalent and severe food allergies worldwide, particularly affecting infants and children. Increasing incidence rates across major markets continue to create substantial demand for effective treatment and prevention strategies.

Current Market Landscape and Approved Therapies

The availability of approved therapies such as PALFORZIA and XOLAIR has significantly improved Peanut Allergy management. However, challenges related to continuous dosing requirements, treatment adherence, and patient accessibility continue to drive the development of next-generation therapies.

Clinical Trial Activity in Peanut Allergy

The Peanut Allergy pipeline is highly active, with clinical trials evaluating innovative therapies including Viaskin Peanut Patch, Remibrutinib, PVX108, SLIT-tablets, INP20, INT301, and others targeting multiple immune pathways.

Growing Research and Development Investments

Biopharmaceutical companies are investing heavily in the development of immunotherapy approaches including oral, sublingual, and epicutaneous immunotherapies aimed at improving desensitization and long-term tolerance.

Increasing Awareness and Diagnosis

Growing awareness regarding food allergy management, improved diagnostic tools, and updated clinical guidelines supporting early peanut introduction are contributing to earlier diagnosis and better disease management.

Download the report to understand which factors are driving @ Peanut Allergy epidemiology trends [https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]

Peanut Allergy Market and Pipeline Analysis

The evolving Peanut Allergy Treatment Market landscape features robust clinical development activities led by DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (SLIT-Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), and Regeneron Pharmaceuticals (Linvoseltamab + Dupilumab).

Peanut Allergy Understanding

Peanut Allergy is a severe IgE-mediated immune disorder triggered by exposure to peanut proteins. The condition is associated with potentially life-threatening allergic reactions including anaphylaxis, significantly impacting patient quality of life and increasing healthcare burden.

Upon allergen exposure, Th2 immune responses stimulate IgE antibody production, which binds to mast cells and basophils. Subsequent allergen re-exposure activates these sensitized cells, leading to histamine release and inflammatory cascades responsible for allergic symptoms.

Peanut Allergy Diagnosis

Diagnosis of Peanut Allergy primarily relies on clinical history combined with confirmatory diagnostic testing. The gold standard remains the Double-Blind Placebo-Controlled Food Challenge (DBPCFC).

Additional diagnostic methods include:

- Skin Prick Tests (SPT)

- Serum IgE Testing

- Molecular Allergy Diagnostics

- Oral Food Challenge (OFC)

- Basophil Activation Testing

- Bead-based Epitope Assays (BBEA)

Advancements in molecular diagnostics and artificial intelligence-assisted allergy diagnostics are expected to improve diagnostic precision in the coming years.

Peanut Allergy Treatment Market

Current Peanut Allergy management strategies focus on allergen avoidance and emergency epinephrine administration for anaphylaxis management. However, immunotherapy approaches are transforming the treatment landscape.

Major immunotherapy strategies include:

- Oral Immunotherapy (OIT)

- Sublingual Immunotherapy (SLIT)

- Epicutaneous Immunotherapy (EPIT)

Desensitization therapies are improving patient outcomes by increasing tolerance thresholds and reducing the risk of accidental allergic reactions.

Get In-Depth Knowledge on Peanut Allergy Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Peanut Allergy Marketed Drugs

- PALFORZIA (peanut allergen powder-dnfp): Stallergenes Greer

PALFORZIA is the first FDA-approved oral immunotherapy for Peanut Allergy, designed to gradually reduce allergic sensitivity through controlled allergen exposure. Despite demonstrating efficacy, treatment adherence challenges and safety concerns continue to impact broader adoption.

- XOLAIR (omalizumab): Roche and Novartis

XOLAIR received FDA approval for reducing allergic reactions, including anaphylaxis, in patients with IgE-mediated food allergy aged one year and older. The therapy represents a significant advancement in Peanut Allergy treatment by targeting and blocking IgE pathways.

Peanut Allergy Emerging Therapies

- Viaskin (DBV712) Peanut Patch: DBV Technologies

Viaskin Peanut utilizes epicutaneous immunotherapy to deliver controlled peanut protein exposure through a wearable patch. The therapy has received both Fast Track and Breakthrough Therapy Designations from the FDA and is currently in Phase III clinical development.

- Remibrutinib (LOU064): Novartis

Remibrutinib is a highly selective oral BTK inhibitor under investigation for Peanut Allergy and other immune-mediated disorders. The therapy is currently being evaluated in Phase II clinical trials.

- PVX108 (AVX-201): Aravax

PVX108 is designed to target T-cell mediated immune responses and potentially reverse allergic disease progression in pediatric Peanut Allergy patients.

Peanut Allergy Drugs Class Analysis

BTK inhibitors represent a promising class of emerging therapies for Peanut Allergy by suppressing mast cell and basophil activation through inhibition of intracellular signaling pathways. These therapies may provide rapid prophylactic protection against allergic reactions and accidental allergen exposure.

Other emerging therapeutic classes include:

- Immunomodulators

- Immunostimulants

- Immunosuppressants

- Cytotoxic T-lymphocyte stimulants combined with IL-13 receptor inhibitors

Peanut Allergy Market Outlook

The Peanut Allergy Treatment Market is expected to undergo substantial transformation during the forecast period owing to increasing disease prevalence, growing awareness, and expanding therapeutic innovation.

The launch of emerging therapies such as Viaskin Peanut Patch, Remibrutinib, and other novel immunotherapies is anticipated to significantly improve treatment accessibility, convenience, and patient outcomes.

Among the 7MM, the United States accounted for the largest Peanut Allergy Treatment Market Size, valued at approximately USD 340 million in 2024.

Viaskin Peanut Patch is expected to emerge as one of the leading non-invasive treatment options for pediatric patients due to its favorable safety profile and convenient administration approach.

Scope of the Peanut Allergy Treatment Market Report

- Coverage: 7MM

- Study Period: 2020-2034

- Forecast Period: 2025-2034

- Geographies Covered: United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan

- Peanut Allergy Companies: DBV Technologies, Novartis, Aravax, ALK-Abello, InnoUp Farma, Allergy Therapeutics, Intrommune Therapeutics, Roche, Regeneron Pharmaceuticals, and others.

- Peanut Allergy Therapies: PALFORZIA, XOLAIR, Viaskin Peanut Patch, Remibrutinib, PVX108, SLIT-Tablet, INP20, INT301, and others.

Unlock Strategic Insights with DelveInsight's Comprehensive Peanut Allergy Treatment Market Report @ https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Peanut Allergy Epidemiology and Market Forecast Methodology

5. Peanut Allergy Market Overview at a Glance

6. Disease Background and Overview

7. Peanut Allergy Diagnosis and Treatment Guidelines

8. Epidemiology and Patient Population

9. Peanut Allergy Emerging Therapies

10. Peanut Allergy Market Analysis

11. Peanut Allergy Drugs Uptake

12. Unmet Needs

13. SWOT Analysis

14. KOL Views

15. Market Access and Reimbursement

16. Competitive Intelligence Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm specializing in life sciences and healthcare intelligence. The company provides comprehensive market research reports, epidemiology forecasts, competitive intelligence, and strategic insights to support informed business decisions for pharmaceutical, biotechnology, and healthcare organizations worldwide.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peanut-allergy-treatment-market-size-in-the-7mm-was-valued-at-usd-533-million-in-2025-and-is-expected-to-reach-usd-2464-million-by-2034-growing-at-a-cagr-of-1850-estimates-delveinsight]
Phone: +919650213330
Address:63, M3M 113 Market, Sector 113
City: Gurugram
State: https://www.delveinsight.com/
Country: India
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.